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Prognosis in obesity
Older people should not be misinformed
about being overweight
Editor—With reference to the editorial by
Lean on prognosis in obesity,1 advising
apparently overweight older people to lose
weight may do more harm than good.
Evidence suggests that the risks of being
“overweight” decrease with increasing age.
On the basis of mortality, the ideal bodymass
index (BMI) is higher in older than young
adults, with an optimum BMI for people
older than 65 in the young adult “over-
weight” range of 27-30 kg/m2.2 In a
systematic review, Heiat et al concluded that
the relation between BMI and mortality in
people older than 65 is a flat bottomed, U-
shaped curve, with mortality rising only at
BMI > 31 kg/m2 and perhaps not at any
BMI in people older than 75.2
Weight loss is more common than weight
gain in older people, and associated with poor
outcomes, even when the weight loss is
intentional and the person was
“overweight” at baseline.3–5 In
the prospective cardiovascular
health study of some 4700
community dwelling people
older than 65, weight loss of
more than 5% over three years
was substantially more com-
mon than weight gain of more
than 5%.3 Weight loss, but not
weight gain, was associated
with a significantly increased
risk of mortality (relative risk
1.67, 95% confidence interval
1.29 to 2.15).3 The association
of increased mortality with
weight loss persisted even at
the highest third of baseline weight.3 In a study
of older men with BMI ≥ 30 kg/m2, inten-
tional weight loss was associated (P < 0.001)
with a greater rate of hip bone loss
( − 1.7%/year) than inmen with no weight loss
( − 0.1%/year) or weight gain (0.5%/year).5
The indiscriminate application of evi-
dence from studies in younger adults to the
management of older people is hazardous.
We believe that many older people are trying
to lose weight inappropriately. There is a
need to ensure that most of our elders are
given appropriate advice: “Keep physically
active, eat sensibly, and maintain weight.”
Renuka Visvanathan senior lecturer in geriatric medicine
renuka.visvanathan@adelaide.edu.au
Ian Chapman associate professor
Department of Medicine, University of Adelaide,
SA 5011, Australia
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Obstacles must be removed to prevent
obesity through increased physical activity
Editor—In his editorial Lean proposes that
we all eat a little less (0.418 mJ/day) and
walk a little more (0.418 mJ/day, equivalent
to 2000 steps) to prevent 90% of obesity.1 If
such recommendations work,
they may seem a reasonable
sacrifice for individual people
and therefore could work in
practice. To promote physical
activity, however, we as a soci-
ety face ever larger obstacles,
mainly increased stress and
an increasingly hostile envi-
ronment (car clogged streets,
threat of crime, and lack of
parks and bicycle lanes).
Moreover, we now have more
calorie saving machines than
ever—cars, lifts, computers,
electric toothbrushes, etc—
with more labour saving
gadgets being developed and marketed on a
seemingly daily basis.
Today the average adult in western
Europe walks about 8000-9000 steps daily.
Among the Amish people in North
America, who refrain from using electricity
and cars, men accumulate 18 425 steps daily
(0% obesity) and women 14 196 (9%
obesity).2 The promotion of lifestyle physical
activity, carried out as a routine part of daily
living as practised by the Amish, is critical
for long term adherence. A similar but more
realistic strategy for promoting longstand-
ing physical activity routines is physically
active transport, such as walking to and from
the bus stop or bicycling to and from work.
The current trend, however, is that we drive
shorter and shorter distances, with public
transport services deemed too unreliable
and slow.
We need to provide people with a realis-
tic chance of achieving the necessary
lifestyle change—for example, by creating
car free areas where people live; safe and
well lit parks and bicycle lanes, especially
between the home and school or work; reli-
able public transport; shower facilities at
work; and reduced perceived time pressures.
We also need careful analysis of lifestyle
change recommendations—is their efficacy
established, can they be converted into
practice?
Erik Hemmingsson health educator
Obesity Unit, Karolinska University Hospital,
SE-141 86 Stockholm, Sweden
erik.hemmingsson@medhs.ki.se
Competing interests: None declared.
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Obesity in severe mental illness poses
particular problems
Editor—Lean’s editorial on prognosis in
obesity is a timely contribution to the litera-
ture on the relation between increasing
weight and physical morbidity and mortality
in the general population.1 Obesity is also a
problem in people with severe mental
illness. Major depressive disorder, bipolar
disorders, and schizophrenia rank among
the top 10 causes of disability worldwide,2
and this group of patients has excess physi-
cal morbidity and reduced life expectancy
(less than half of which is accounted for by
suicide3).
Metabolic diseases, including obesity, are
likely to contribute to increased mortality in
this population. Whether mental illness in
itself is an independent risk factor for the
development of obesity and other compo-
nents of the metabolic syndrome or whether
metabolic dysfunction is simply secondary
to lifestyle remains unclear. Iatrogenic
causes of obesity are also likely to be impor-
tant as atypical antipsychotic drugs—a com-
monly prescribed class of psychotropic
drugs—cause weight gain, disorders of
glucose homeostasis, and hyperlipidaemia.4
A high prevalence of undiagnosed and
untreated metabolic disease, including obes-
ity, has recently been reported in psychiatric
patients taking antipsychotic drugs,5 which
may reflect poor monitoring and interven-
tion owing to a lack of awareness in primary
and secondary care of this important public
health issue. Recent consensus statements
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make clear the need for monitoring
metabolic disease in patients prescribed
antipsychotic drugs.4
Although the first law of thermodynam-
ics (“move a little more, eat a little less”1) may
hold scientific truth and credibility for
people motivated to lose weight and poten-
tially increase longevity, many of the core
psychopathological features of patients with
severe mental illness (depressed mood, lack
of motivation, hopelessness, disorganised
thinking, etc) conspire against such lifestyle
changes.
Paul Mackin academic specialist registrar in psychiatry
paul.mackin@ncl.ac.uk
Allan H Young professor of psychiatry
Department of Psychiatry, University of Newcastle
upon Tyne, Royal Victoria Infirmary, Newcastle
upon Tyne NE1 4LP
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Author’s reply
Editor—In principle it is correct to
consider whether advice to younger people
is appropriate to older people. With regard
to obesity, the evidence on intentional
weight loss is scanty and mainly based on
self reports. Our study of intentional (at
least intended) and measured weight loss
among older patients with type 2 diabetes
(mean age 64) followed up as a cohort until
death, showed a strong positive association
with life expectancy: weight loss of 10 kg
was associated with three to four years’
increased survival.1
However, it should be remembered that
obesity is not primarily a killing disease. Its
main impact, increasingly with age, is on dis-
ability and quality of life through aggrava-
tion of a vast range of symptoms, including
tiredness, breathlessness, back pain, arthritis,
stress incontinence, depression—and the list
goes on.
Hemmingsson has called for proper
evaluation of diet and physical activity inter-
ventions to prevent obesity. A reluctance
remains to fund proper evaluation of
preventive interventions. The development
and evaluation of a new drug to reduce a
cardiovascular risk factor, and possibly delay
cardiac events by a few weeks, now costs well
over £200-500m. The development and
evaluation of an evidence based interven-
tion to manage obesity by diet and exercise
in primary care, the Counterweight pro-
gramme,2 cost about £5m.A recent proposal
to develop and evaluate a family based
programme to prevent weight gain, obesity,
and metabolic consequences, based
on America on the Move and using the
existing Counterweight team, was costed at
£835 000 and was not even evaluated as a
full proposal when submitted to the Medical
Research Council under the National
Prevention Research Initiative, whose total
budget for all disease prevention was only
£12m.
Mackin and Young refer to the invidious
cycle between weight gain and mental ill
health, which conspires against making sus-
tainable lifestyle changes for losing weight.
This issue is particularly serious for patients
prescribed the many antipsychotic drugs
that stimulate increased food consumption.
Mackin and Young are right: the priority
should be primary prevention of excess and
unwanted weight gain in adults.
M E J Lean professor
lean@clinmed.gla.ac.uk
Division of Developmental Medicine, Human
Nutrition, University of Glasgow, Royal Infirmary,
Glasgow G31 2ER
Competing interests: None declared.
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Early life risk factors for
obesity in childhood
The hand that rocks the cradle rules the
world
Editor—The survey by Reilly et al to iden-
tify the risk factors for obesity in children
seems to have been well designed, meticu-
lously conducted, and rigorously analysed. 1
But as someone who is neither especially
numerate nor an expert in this research
topic, I had to read the paper three times
and consult a statistician colleague to
confirm that the authors had systematically
controlled for maternal education—a proxy
for social class—in every item in their
analysis.
In other words, in their conclusion
“Eight factors in early life are associated with
an increased risk of obesity in childhood,”
the authors might (for the benefit of the
general practitioner on the Clapham omni-
bus) have inserted the qualifier “that is,
AFTER controlling for maternal education,
which was confirmed by this study to be
highly significantly related to the develop-
ment of obesity in children.”
Having (rightly, I’m sure, from a statisti-
cal standpoint) controlled so carefully for
maternal education, the authors then do not
mention it in their discussion of potentially
modifiable risk factors for childhood obesity.
Their recommendations seem to focus on
technical tweaks targeted at metabolic
variables, but my own hypothesis as a
general practitioner is that interventions
aimed at increasing the health literacy of the
primary caregiver have far greater potential
for achieving a slimmer cohort of primary
school children.
I would value comment on this sugges-
tion from both the authors and practitioners
who try to influence the rate of weight gain
of their youngest patients.
Trisha Greenhalgh professor of primary health care
University College London, London N19 5LW
p.greenhalgh@pcps.ucl.ac.uk
Thanks to Richard Morris for advice on the statisti-
cal aspects of the paper.
Competing interests: None declared.
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Early feeding is crucial target for
preventing obesity in children
Editor—Reilly et al present their findings
on some early life risk factors for obesity at
age 7 in a cohort of 7758 children born in
the early 1990s.1 We believe that their
conclusions about breast feeding and time
of weaning are flawed.
The investigators infer that these early
feeding factors are unimportant because
they are not independently associated with
the obesity outcome in a statistical model
that includes more proximal, parental, and
prenatal factors. If early feeding factors exert
their influence on childhood obesity largely
through a causal pathway that includes
other factors in the investigators’ statistical
models then it is not surprising that the early
feeding factors do not emerge as independ-
ent predictors: it is a mistake to infer that
these factors are therefore unimportant.
The central public health issue is to identify
the modifiable risk factors that can reason-
ably be assumed to be causal for obesity in
children.
We believe that there is sufficient
bio-behavioural and epidemiological evi-
dence to support the idea that infant feeding
practice directly affects early weight gain,
and that trials of early feeding interventions
to prevent later obesity in children are
justified.2–5 The investigators’ univariate find-
ings that early feeding factors predict later
obesity add to this evidence, and their multi-
variate results should not be used to weaken
the evidence on grounds of specious
confounding. These data could be reana-
lysed with more attention paid to plausibly
causal pathways.
Iain E Buchan senior lecturer
buchan@manchester.ac.uk
Richard F Heller professor
Peter Clayton professor
Medical School, University of Manchester,
Manchester M13 9PT
Peter E Bundred reader
Department of Primary Care, University of
Liverpool, Liverpool L69 3GB
Tim J Cole professor
Institute of Child Health, University College
London, London WC1N 1EH
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Authors’ reply
Editor—Greenhalgh and Buchan et al
focus on interpretation of our results and
the implications for obesity prevention. We
adjusted for maternal education because it
influenced both the potential risk factors
and the outcome (obesity). Greenhalgh
highlights the importance of socioeconomic
status, although all social groups have been
affected by the obesity epidemic.1 Targeting
maternal education may be useful in obesity
prevention, but there is currently no (mater-
nal) educational or socioeconomic interven-
tion that successfully prevents obesity in
children.2
Buchan et al recommend early feeding
factors as targets of obesity prevention
initiatives. Our results do not rule out a role
for infant feeding as a cause of obesity.
Breast feeding was protective against later
obesity in two out of three statistical models,
but not in our final model for reasons
discussed in the paper. Evidence for timing
of introduction of complementary foods,
derived from analysis of 21 potential risk
factors in the entire sample, was inconclu-
sive. A systematic review was not supportive
of timing of introduction of complementary
feeding as a risk factor,3 and it is unlikely that
it could have operated via the other factors
in our final model (birth weight, parental
obesity, sleep, and TV viewing at age 3) as
suggested by Buchan et al. However, a more
detailed analysis of a wider range of early
feeding factors would be desirable.
Preventive interventions for childhood
obesity should meet certain criteria.4 5 At
present, these criteria may be met by few
strategies: promoting breast feeding, reduc-
ing sedentary behaviour, and reducing the
consumption of sugar sweetened drinks.
Future interventions are probably most
likely to succeed if they target these
behaviours. Attempting to modify timing of
introduction of complementary feeding
might be beneficial in other respects but
seems premature as a strategy for obesity
prevention at this stage.
John J Reilly reader in paediatric energy metabolism
jjr2y@clinmed.gla.ac.uk
Julie Armstrong lecturer in nutrition
University of Glasgow Division of Developmental
Medicine, Yorkhill Hospitals, Glasgow G3 8SJ
Pauline Emmett senior research fellow in nutrition
Andy Ness senior lecturer in epidemiology
Andrea Sherriff research fellow in medical statistics
Unit of Paediatric and Perinatal Epidemiology,
Institute of Child Health, University of Bristol
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Obesity in middle age and
future risk of dementia
Problem is probably greater for women
Editor—The paper by Whitmer et al
supports the findings of an earlier study in
showing that obesity in middle age predicts
dementia in older age.1 2 The major appar-
ent weakness of the study is the loss of
13 014 patients to follow-up. Their adiposity
and sociodemographic characteristics at
study entry (1964-73: n = 25 290) were
reported to be the same as those who were
followed up to 1994-2003. That is impor-
tant. Their medical and physical characteris-
tics are also important. We are left to accept
that they were similar also. The similarity or
otherwise needs to be presented with the
paper.
Table 1 shows some marked differences
among the people who were later diagnosed
with dementia: education to grade school
level only (11.1%) compared with additional
education (6.9%), black race (8.9%) com-
pared with white race (7.1%) and Asian or
other races (5.5%). Adjustment for these
confounders did apparently not modify the
risk of the diagnosis of dementia related to
obesity significantly.
The effect of obesity and overweight was
more apparent in women. The lesser effect
of obesity in men is dealt with by the
statement that there were fewer obese and
overweight men and that the power to detect
an effect was therefore reduced. It is,
however, clear from the text and table 2 that
there were in fact more obese and
overweight men (n = 2546) than women
(n = 1804).
Further confusion arises from consid-
eration of the sister paper derived from
the same database.3 In that paper the effects
of midlife risk factors (smoking, hyperten-
sion, cholesterol, and diabetes) on the
subsequent diagnosis of dementia are
reported. The exclusion of people with
missing data reduces to 8845 the numbers
followed up to 1994-2003. Fewer subjects
have not been diagnosed with dementia
(8124 v 9563), yet more are so diagnosed
(721 v 713). How that came about is difficult
to explain unless the follow-up was longer.
Reading the two papers together indicates
no difference in time bases for acquisition
of the data.
Despite problems the paper by Whitmer
et al shows that dementia in women
(probably) and in men (possibly) is influ-
enced by obesity in the middle of life and
late life and overweight, determined by body
mass index, and supported by measures of
skinfold thickness. A study from Sweden
generated similar conclusions, applicable to
women but not to men.4
Alan J Goble cardiology consultant
Heart Research Centre, Melbourne, VIC 3050,
Australia
heart@medicine.unimelb.edu.au
Competing interests: None declared.
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Dietary fat and sugar may hold the clue
Editor—Whitmer et al report further
evidence supporting the association
between obesity and dementia.1 Although
the mechanism is still far from being under-
stood, the authors alluded to the involve-
ment of adiposity with inflammation and its
markers.
One possible mechanism linking obes-
ity with dementia is oxidative stress
resulting from an increased intake of
processed sugars and fats, which is the hall-
mark of the modern diet. Rats maintained
on a diet high in refined sugar and fat gen-
erated higher concentrations of free radi-
cals.2 3 In contrast, caloric restriction in
animals leads to reduced production of free
radicals by mitochondria and increased
longevity.4
Whitmer et al acknowledge that the lack
of nutritional assessment was a limitation of
their study. If such data had been available
they would have shed light specifically on a
possible relation between fat and sugar
intake and risk of dementia, especially as a
diet rich in these substances is linked to
obesity. We recently showed that patients
with dementia eating a diet high in fat and
carbohydrates have an increased blood
activity of glutathione peroxidase, an endog-
enous antioxidant, which may be a compen-
satory response to an increased oxidative
stress in dementia.5
Whitmer et al say that all cause dementia
diagnoses included dementia, Alzheimer’s
disease, and vascular dementia.1 However,
their data did not include differentiation
between these subsets, especially between
Alzheimer’s disease and vascular dementia.
Whether obesity was preferentially associ-
ated with either vascular dementia or Alzhe-
imer’s disease, or both, would be interesting,
especially as the neuropathological aetiol-
ogy of these two disorders is different.
Naji Tabet senior lecturer in old age psychiatry
Postgraduate Medical School, Faculty of Health,
University of Brighton, Brighton BN1 9PH
n.t.tabet@brighton.ac.uk
Competing interests: None declared.
1 Whitmer RA, Gunderson EP, Barrett-Connor E, Quesen-
berry CP, Yaffe K. Obesity in middle age and future risk of
dementia: a 27 year longitudinal population based study.
BMJ 2005;330:1360-2. (11 June.)
Letters
454 BMJ VOLUME 331 20-27 AUGUST 2005 bmj.com
 on 27 November 2008 bmj.comDownloaded from 
2 Hennig B, Slim R, Toborek M, Malecki A, Robertson LW.
Effects of lipids and antioxidants on PCB-mediated
dysfunction of vascular endothelial cells (EC). Central Eur J
Public Health 2000;8:S18-9.
3 Kashiwagi A, Shinozaki K, Nishio Y, Okamura T, Toda N,
Kikkawa R. Free radical production in endothelial cells
as a pathogenetic factor vascular dysfunction in the
insulin resistance state. Diabetes Res Clin Pract 1999;45:
199-203.
4 Gredilla R, Barja G. The role of oxidative stress in relation
to caloric restriction and longevity. Endocrinology 2005;
26:Epub1-20.
5 Tabet N, Mantle D, Walker Z, Orrell M. Higher fat and car-
bohydrate intake in dementia patients is associated with
increased blood glutathione peroxidase activity. Int Psycho-
geriatr 2005;17:91-8.
Midlife obesity increases risk of future
dementia
Editor—Whitmer et al reported a prospec-
tive study showing that obesity in middle age
was associated with increased risk of future
dementia.1 However, little information was
given on the types of dementia. This is
important especially in Alzheimer’s disease,
in which vascular risk factors might contrib-
ute to its development.2 We have investigated
the relation between Alzheimer’s disease
and obesity throughout adult life in a small
case-control study.
We recruited 25 patients with probable
Alzheimer’s disease from the Launceston
Memory Disorders Clinic, Tasmania, and 50
controls from the local community. Patients
were living at home and were physically well,
with no important medical problems.
Current height, weight, and waist circumfer-
ence were measured. In addition, we asked
participants to recall their weight at the age
of 20-25 and 40-45. Self reported weight has
been shown to be highly correlated with
direct measurement in cognitively healthy
people and those with mild to moderate
dementia.3 4
The mean age of patients with Alzheim-
er’s disease and controls was 74.9 (range
57-88) and 72.1 (65-94), respectively. The
mean mini-mental state examination score
was 19.0 (4-26) for patients with Alzheimer’s
disease and 29.6 (28-30) for controls. Most
patients had mild to moderate disease (80%
with scores greater than 14). The table
shows that at midlife, patients with
Alzheimer’s disease had higher body mass
index (BMI) by 2.8 kg/m2 or 12% than
controls. At late life, BMI was not signifi-
cantly different, but the waist circumference
in patients with Alzheimer’s disease was
higher than in controls by 6.1 cm, or 7%.
Our study supports the conclusion of
Whitmer et al that midlife obesity increases
the risk of future dementia, in this case
Alzheimer’s disease. In addition, abdominal
obesity, which is highly associated with insu-
lin resistance and cardiovascular diseases,
might also be a risk factor for Alzheimer’s
disease.
George Razay senior lecturer in geriatric medicine
and director of research
george.razay@dhhs.tas.gov.au
Anthea Vreugdenhil research coordinator
Launceston General Hospital, Launceston,
Tasmania 7250, Australia
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Authors’ reply
Editor—The study that Goble referenced as
also investigating midlife obesity and
dementia was conducted in subjects with
obesity measurements at age 70.1
Goble questions whether the midlife
health status of those who left the health
plan was similar to those who remained, and
the comparison of dementia cases between
this study and another from the same
cohort.2 The midlife physical characteristics
(cholesterol, blood pressure, and diabetes)
did not differ between those who left or
stayed in the plan. The eight count
difference in dementia cases in our two
studies is the result of a difference in cohorts
based on age categorisation in midlife and
availability of adiposity data.
Dementia had a lower prevalence in
men than in women (6.7 % v 7.11 %). The
power to detect effects may therefore be
slightly reduced in men. Additionally, men
were slightly less likely to be obese (9.97% v
10.1% ). A much greater proportion of men
than women was overweight (48% v 25%),
and the magnitude as well as the significance
of the hazard ratio for overweight men was
much smaller than that for women.
This could have several reasons, includ-
ing competing risk, or a true sex difference
in the effect of body mass index (BMI) on
risk of dementia. The most likely explana-
tion seems to be that the standard cut-off
points set by the World Health Organization
for overweight may be an insensitive
measure of adiposity. BMI tends to overesti-
mate adiposity in those with high muscle
and bone mass; therefore some men in the
overweight category may have had an “over-
weight” BMI but low actual adiposity.3 This is
substantiated by the fact that we found no
significant sex differences in the effect of
skinfold thickness on risk of dementia—the
effect of subscapular skinfold thickness was
even stronger in men (hazard ratio 1.97
(95% confidence interval 1.36 to 2.85)) than
women (1.52 (1.11 to 2.08)). If adiposity and
risk of dementia in men were not associated,
then we would not have seen an effect of
skinfold thickness on risk of dementia in
men as well as women.
We disagree with Goble that the
problem is for women only, an earlier larger
study from Sweden of men only found that
overweight and obese categories of BMI
increased risk of dementia.4 Goble cites this
study as that of women only.
We could not present risks of BMI and
skinfold thickness associated with subtypes
of dementia since most of our diagnoses
came from primary care doctors, and were
coded as “dementia.” Our future work will
focus on risk factors for dementia subtypes
in our population.
Razay and Vreugdenhil’s confirmatory
findings in a case-control study that late life
waist circumference is greater in patients
with Alzheimer’s disease are especially inter-
esting because of the implications of the
effects of central adiposity and the metabolic
syndrome on cognitive health.5
Rachel Whitmer gerontological epidemiologist
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Include measurement of waist
circumference in GP contract
Editor—Abdominal obesity, as measured
by waist circumference, is a key predictive
measurement of metabolic and cardiovascu-
lar risk, more accurate than the measure-
ment of body mass index (BMI) alone.1
Although there is some debate over the
exact threshold, the principle is clear—a
measurement of over 100 cm is regarded as
substantially increasing risk in men. Waist
circumference should be used as a standard
test to ensure the accurate assessment of
patients at high risk of metabolic and
cardiovascular disease and be given the
Means (standard errors) and logistic regression odds ratios (per standard deviation) for BMI and waist






BMI at age 25 (3.5 kg/m2) 23.5 (0.9) 22.8 (0.5) 1.16 (0.64 to 2.10)
BMI at age 45 (3.9 kg/m2) 27.1 (0.9) 24.3 (0.6)* 2.06 (1.01 to 4.21)
BMI at age 65+ (4.1 kg/m2) 26.5 (1.0) 25.5 (0.6) 1.24 (0.68 to 2.26)
Waist circumference (11 cm) 88.4 (3.3) 82.3 (3.2)* 2.05 (0.99 to 4.26)
P<0.05, calculated by using general linear model analysis.
BMI=body mass index
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same importance as routine blood pressure
or cholesterol checks.
Abdominal obesity is a measure of
excess visceral fat. Visceral fat, the accumula-
tion of adipose tissue within the omentum,
abdomen, and around abdominal organs
can be assessed simply by measuring waist
circumference. It is a key factor in the devel-
opment and progression of cardiovascular
disease. The close proximity of visceral fat to
the hepatic portal circulation, and the
cytokines (including tumour necrosis factor
, interleukin-6, and C reactive proteins)
secreted by the adipocytes may directly
influence risk factors associated with the
development of cardiovascular disease.2
Waist circumference is therefore an effective
and simple tool that could be integrated into
general practice.
Weight reduction in obese patients at
risk of cardiovascular disease is associated
with an improvement in metabolic factors
and improved glycaemic control.3 A modest
reduction in weight of 5-10% has been
shown to lead to notable reductions in blood
pressure, thrombogenic potential, and
inflammatory markers, as well as improve-
ments in lipid profile and insulin sensitivity.4
Recent studies support the benefits of
reducing waist circumference to improve
metabolic parameters and cardiovascular
risk.5
An urgent need therefore exists to
include the measurement of waist circumfer-
ence in the current review of the GP
contract (GMSII). Its inclusion would enable
both easier identification of high risk
patients and earlier implementation of man-
agement strategies.
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Audit is important part of
drug safety and regulation
Editor—Waller et al write about the
responsibilities of the pharmaceutical com-
panies and the regulating agencies such as
the UK Medicines and Healthcare products
Regulatory Agency to improve the safety of
the drugs that are licensed for prescription.1
Although cyclo-oxygenase 2 inhibitors and
selective serotonin reuptake inhibitors have
been under the spotlight in recent months,
other drugs may be of greater concern.
In 2000 the National Institute for Health
and Clinical Excellence (NICE) issued guid-
ance on the use of proton pump inhibitors
in treating dyspepsia.2 In January 2005 in
our hospital, an audit of record of 50
deceased patients identified 20 who were
taking these drugs. Twelve of the 50 patients
had had Clostridium difficile isolated in
recent months, and eight of them had been
taking proton pump inhibitors. Forty three
patients received one or more antibiotics, 29
received three or more (cephalosporins 27,
co-amoxiclav 19, metronidazole 19, clari-
thromycin 14; five or fewer had received
nine other antibiotics).
Studies in Plymouth in 2003 and
Montreal in 2004 indicated that using
proton pump inhibitors, especially in the
long term, compounded with other preci-
pitators such as multiple antibiotic usage
and nasogastric feeding, more than
doubled the incidence of infection with C
difficile.3 4
As a profession, we have the responsibil-
ity to follow the advice of agencies such as
NICE about prescribing and to audit the
effects of our treatments on our patients. We
are looking at deceased patients’ records in
blocks of 50 using some of the trigger tools
recommended by the Institute for Health-
care Improvement.
This audit has led to several improve-
ments already and highlighted the rapidly
increasing popularity of proton pump
inhibitors for infirm elderly people, who are
most at risk of C difficile infection. Although
some of these patients with C difficile died as
a result of the organism’s effects, the new
North American strain was not identified.
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Dissemination of results needs
to be tracked as well as the
funding is
Editor—Decullier et al evaluated some of
the factors influencing publication of health
related research projects.1 They examined
research activity outcomes from the per-
spective of research ethics approval.
Registration of clinical trials is not
universally required, and sponsor databases
are necessarily limited in scope. However,
approval by a research ethics committee is
required for all research on human subjects
and includes protocols regardless of funding
status and origin. We agree with this
approach and believe that research ethics
approval is the earliest convergence in the
birth of research projects on human subjects
and an ideal perspective from which to study
the subsequent events in a project’s life cycle.
Failure to disseminate results is consid-
ered to be research misconduct and is an
urgent scientific and ethical concern.2 3 As
confirmed by Decullier et al, selective
dissemination of research results in publica-
tion bias, typically skewing the literature
towards reports with positive findings. In
their discussion, however, Decullier et al
seem to conflate the issue of clinical trial
registration with that of selective dissemina-
tion, implying that registration will remedy
this situation.
Although the registration models pro-
moted by the International Council of
Medical Journal Editors, the Canadian Insti-
tutes of Health Research, European regula-
tory agencies, and others increase transpar-
ency, they are not designed to ensure that
registered protocols result in publication but
to ensure that publications are spawned only
from registered protocols.
Preliminary results from a study we are
undertaking in Canada indicate that,
although meticulous financial records of
research activity are kept, mechanisms for
identifying and tracking the dissemination
status of research projects including human
subjects are almost non-existent.
We hope to build on the work of Decul-
lier et al by characterising the range of
dissemination (from local presentation to
global distribution) that is relevant to
clinicians in contemporary practice, identify-
ing trends over time in modes of dissemina-
tion (oral, written, and electronic), and
clarifying the mechanisms required to
increase rates of dissemination as a means of
enhancing the value, integrity, and the pub-
lic’s trust in clinical research.
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